pazopanib

P3, N=129, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027

P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center

P2/3, N=140, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

Rutin, trifolin (a kaempferol glycoside), and epigallocatechin exhibited the strongest binding (e.g. rutin: - 8.85 kcal/mol to VEGF-A), surpassing the reference inhibitor Pazopanib (- 3.56 kcal/mol) with multiple stabilizing interactions with these proteins, suggesting potential to interfere with tumor angiogenesis and cell survival pathways. Collectively, these findings provide a scientific basis for the traditional use of T. globiferus and support its fraction as promising sources of multi-targeted anticancer agents. The identification of bioactive compounds further establishes a foundation for bioassay-guided isolation, mechanistic validation, and future drug development.

P1/2, N=51, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026

The AI-guided screening of approved and investigational drug libraries to identify compounds predicted to reverse subtype-specific molecular programs; preclinical studies highlight candidates such as pazopanib and histone deacetylase (HDAC) inhibitors is discussed...Integrating surgical management, multi-omics, and computational pharmacology helps bridge the gap from bench to bedside and, ultimately, improve outcomes for patients with RLMS. In contrast to prior work that addresses molecular subtyping or surgical management in isolation, this review presents an integrative framework that links surgical risk stratification with transcriptomic profiling to enable AI-guided drug repurposing and provides a roadmap for personalized RLMS therapy.

P=N/A, N=20, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028

He underwent nephrectomy, followed by hepatic recurrence treated with pazopanib and subsequent axitinib. Based on these findings, everolimus, a mammalian/mechanistic target of rapamycin (mTOR) inhibitor, was recommended, which markedly reduced the size of the metastatic lesions and was continued for 24 months until disease progression without severe adverse events. This case suggests that CGP can help identify actionable alterations in eAML, such as TSC2 mutations, to guide personalized therapy with mTOR inhibitors.

pneumoniae suppressed S-nitrosylation of tripartite motif containing protein 28 (TRIM28) by diminishing Mn2+ levels, allowing TRIM28 to physically interact with the transcription factor SP1 to promote the transcription of solute carrier family 27 member 1 (SLC27A1) and lipid deposition. Taken together, these findings indicate that tumor-resident S. pneumoniae plays an important role in conferring pazopanib resistance, suggesting that S. pneumoniae could serve as a potential biomarker of pazopanib response in ccRCC.

P1/2, N=47, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Feb 2027

To encapsulate our findings, we have determined eight MAPK pathway-associated CRC prognostic biomarkers and developed a prognostic model accordingly. This model has proven effective in stratifying the risk levels among CRC patients.

She subsequently received systemic therapy, initially with temozolomide and later pazopanib, followed by sunitinib. This case illustrates the importance of molecular drivers of cancer in a benign soft-tissue tumor and the potential to offer targeted therapies to extend patient survival. This rare case highlights the potential malignant behavior of nodular fasciitis associated with PPP6R3-USP6 fusion.